Form 4: Vertex Pharmaceuticals EVP Jonathan Biller Reports Stock Transactions
SEC Form 4 Filing
EVP and Chief Legal Officer of Vertex Pharmaceuticals, Jonathan Biller, reports the disposition of shares under a pre-arranged trading plan.
Summary
- Jonathan Biller, EVP and Chief Legal Officer of Vertex Pharmaceuticals, reported transactions involving the company's common stock.
- On October 1, 2024, 630 shares were disposed of to cover tax obligations at a price of $466.84.
- On October 2, 2024, 999 shares were sold at a price of $461.66.
- Following these transactions, Biller directly owns 16,651 shares of Vertex Pharmaceuticals.
- The transactions were executed under a pre-arranged trading plan (Rule 10b5-1) established on February 13, 2024.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Stakeholder Impact
- The transactions may have a minor impact on shareholders as they provide insight into executive stock activity.
Key Dates
| Date | Description |
|---|---|
| 02/13/2024 | Date of entry into Rule 10b5-1 trading plan |
| 10/01/2024 | Disposition of 630 shares to cover tax obligations |
| 10/02/2024 | Sale of 999 shares |
| 10/03/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.